Genzyme to buy back rights Genzyme Corp. of Cambridge, Mass., agreed Thursday to buy back the sales and marketing rights for Synvisc, a pain treatment for people suffering from osteoarthritis of the knee, from Wyeth Pharmaceuticals of Collegeville, Pa.